Benitec Biopharma Reports Positive Results in Gene Therapy Study

Benitec Biopharma Inc. (BNTC) has reported significant improvements in swallowing after administering low-dose BB-301 in OPMD patients, indicating positive potential for its gene therapy advancements.

Date: 13-10-2024

AI Rating: 7

Benitec Biopharma Inc. (BNTC) announced progress in its BB-301 Phase 1b/2a study focused on treating Oculopharyngeal Muscular Dystrophy (OPMD). The report highlights that two subjects treated with the lowest dose of BB-301 exhibited durable improvements in their swallowing capabilities.

Notably, Subject 1, who displayed severe dysphagic symptoms at the beginning of the study, made clinically significant gains as measured by the post-dose Swallowing Specific Quality of Life (SSQ) scores and the Timed Pathological Reflux (TPR) results by Day 270. Subject 2 also showed progress, reaching a swallowing profile indicative of normal function by Day 180.

The strong correlation between SSQ scores and VFSS TPR results underscores the clinical benefits of the treatment. No significant adverse events were reported, which contributes positively to the safety profile of BB-301.

Stocks: BNTC